for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Eli Lilly And Co

LLY.N

Latest Trade

141.21USD

Change

-0.35(-0.25%)

Volume

904,655

Today's Range

139.89

 - 

141.44

52 Week Range

101.41

 - 

142.25

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
141.56
Open
141.16
Volume
904,655
3M AVG Volume
70.78
Today's High
141.44
Today's Low
139.89
52 Week High
142.25
52 Week Low
101.41
Shares Out (MIL)
960.13
Market Cap (MIL)
135,292.00
Forward P/E
--
Dividend (Yield %)
2.10

Next Event

Q4 2019 Eli Lilly and Co Earnings Release

Latest Developments

More

Lilly Expands Insulin Affordability Options With Lower Priced Options

Tyvyt Combined With Alimta And Platinum Met Predefined Primary Endpoint In Phase 3 Orient-11 Study As First-Line Therapy In Nonsquamous Nsclc

Dermira To Pay Eli Lilly $40 Million If Deal Terminated

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Eli Lilly And Co

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Contact Info

Lilly Corporate Ctr

Drop Code 1094, Lilly Corporate Ctr

+1.317.2762000

https://www.lilly.com/

Executive Leadership

David A. Ricks

Chairman of the Board, President, Chief Executive Officer

Joshua L. Smiley

Chief Financial Officer, Senior Vice President

Aarti S. Shah

Senior Vice President - Chief Information and Digital Officer

Daniel M. Skovronsky

Senior Vice President, Chief Scientific Officer

Melissa Stapleton Barnes

Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer

Key Stats

2.33 mean rating - 15 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

21.2K

2017

22.9K

2018

24.6K

2019(E)

22.2K
EPS (USD)

2016

3.520

2017

4.280

2018

5.550

2019(E)

5.812
Price To Earnings (TTM)
30.34
Price To Sales (TTM)
5.97
Price To Book (MRQ)
40.02
Price To Cash Flow (TTM)
23.82
Total Debt To Equity (MRQ)
450.12
LT Debt To Equity (MRQ)
403.91
Return on Investment (TTM)
14.88
Return on Equity (TTM)
10.77

Latest News

Latest News

Eli Lilly to add eczema drug with $1.1 billion deal for Dermira

Eli Lilly and Co <LLY.N> said on Friday it would buy skin disease specialist Dermira Inc <DERM.O> for about $1.1 billion in cash, bolstering its arsenal with an experimental therapy for skin condition atopic dermatitis.

Eli Lilly sees higher-than-expected 2020 profit

Eli Lilly and Co <LLY.N> on Tuesday forecast a higher-than-expected profit for 2020, citing growing demand for its medicines including diabetes drug Trulicity and psoriatic arthritis treatment Taltz.

Eli Lilly expects higher-than-expected 2020 profit

Eli Lilly and Co on Tuesday forecast a higher-than-expected profit for 2020, citing growing demand for its medicines including diabetes drug Trulicity and psoriatic arthritis treatment Taltz.

FDA panel votes against Lilly-Boehringer Ingelheim's diabetes drug

Independent experts on an FDA advisory panel on Wednesday voted against the use of an already approved diabetes drug from Eli Lilly and Co and Boehringer Ingelheim as an add-on to insulin therapy in patients with type 1 diabetes.

FDA panel votes against Lilly-Boehringer Ingelheim's diabetes drug

Independent experts on an FDA advisory panel on Wednesday voted against the use of an already approved diabetes drug from Eli Lilly and Co and Boehringer Ingelheim as an add-on to insulin therapy in patients with type 1 diabetes.

Sales of Eli Lilly diabetes drug Trulicity fall short, shares drop

Eli Lilly and Co <LLY.N> third-quarter sales missed Wall Street estimates on Wednesday as rebates limited revenue from its top-selling diabetes drug Trulicity, and its shares fell about 4%.

Eli Lilly to target cancer drug developers for deals

Eli Lilly and Co will target cancer drug developers for deals, Chief Executive Officer Dave Ricks said on a post-earnings conference call on Wednesday.

Eli Lilly reports 9% rise in third-quarter profit

Eli Lilly and Co reported a 9.1% increase in third-quarter profit on Wednesday, helped by higher sales of its top-selling diabetes drug, Trulicity, and lower tax expense.

Eli Lilly's migraine treatment wins U.S. FDA approval

The U.S. Food and Drug Administration said on Friday it had approved Eli Lilly and Co's migraine drug, Reyvow.

Study shows Apple devices in combo with apps could identify dementia

Drugmaker Eli Lilly said on Thursday early results from a study suggest that Apple Inc devices, including the iPhone, in combination with digital apps could differentiate people with mild Alzheimer's disease dementia and those without symptoms.

Study shows Apple devices in combo with apps could identify dementia

Drugmaker Eli Lilly said initial results from a study suggest that Apple Inc devices, including the iPhone, in combination with digital apps could differentiate people with mild Alzheimer's disease dementia and those without symptoms.

Newer drugs help Eli Lilly top Wall Street quarterly profit estimate

Eli Lilly and Co <LLY.N> reported a second-quarter profit that topped Wall Street estimates and raised its 2019 earnings forecast on Tuesday, as higher demand for newer drugs offset increased discounts for the U.S. Medicare program and sales declines of medicines that lost...

Eli Lilly tops revenue estimates on diabetes drug boost

Eli Lilly and Co edged past Wall Street estimates for quarterly revenue on Tuesday, as higher sales of its top-selling diabetes drug, Trulicity, helped offset the impact of generic competition on its erectile dysfunction drug, Cialis.

Eli Lilly's hypoglycemia treatment wins FDA approval

The U.S. Food and Drug Administration approved Eli Lilly and Co's treatment for severe hypoglycemia, the health regulator said on Wednesday.

UPDATE 1-Eli Lilly's bio-medicines head to leave next month

Drugmaker Eli Lilly and Co said on Thursday Christi Shaw, president of its bio-medicines business, would leave the company at the end of next month.

Eli Lilly's bio-medicines head to leave next month

Drugmaker Eli Lilly and Co said on Thursday Christi Shaw, president of its bio-medicines business, would leave the company at the end of next month.

U.S. judge strikes down Trump administration rule requiring drug prices in TV ads

A federal judge on Monday dealt a blow to the Trump administration by striking down a new rule that would have forced pharmaceutical companies to include the wholesale prices of their drugs in television advertising.

Eli Lilly misses estimates for top-selling diabetes drug Trulicity, shares slip

Eli Lilly and Co on Tuesday reported lower-than-expected first-quarter sales for its top-selling diabetes drug Trulicity, and the U.S. drugmaker said the need to offer rebates and discounts were taking a toll and likely to weigh on revenue growth for the year.

Eli Lilly quarterly profit more than triples on Elanco gain

Eli Lilly and Co's first-quarter profit more than tripled, as the U.S. drugmaker recorded a $3.7 billion gain from its spin-off of animal health unit Elanco.

Lower dose of Pfizer-Lilly painkiller misses main goals in late stage study

A lower dose of non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co failed to meet main goals in a late-stage study in patients with moderate-to-severe osteoarthritis of the hip or knee, the companies said on Thursday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up